Related Experiment Videos
Giant prolactinomas presenting as skull base tumors
Giuseppe Minniti1, Marie Lise Jaffrain-Rea, Antonio Santoro
1INM-IRCCS Neuromed, Pozzilli, Italy.
Surgical Neurology
|March 21, 2002
Summary
Giant prolactinomas invading the skull base are rare. Measuring prolactin levels in skull base tumors is crucial for accurate diagnosis and treatment, avoiding unnecessary surgery or radiotherapy.
Area of Science:
- Endocrinology
- Neurosurgery
- Oncology
Background:
- Skull base tumors can be challenging to diagnose, with prolactinomas occasionally mimicking nonpituitary neoplasms.
- Giant prolactinomas invading the skull base represent a rare clinical entity.
Observation:
- Four cases of giant prolactinomas with skull base invasion and atypical presentations are detailed.
- Symptoms included headache, nasal obstruction, hearing loss, dizziness, ophthalmoplegia, visual failure, and psychiatric disturbances.
- Diagnosis was confirmed by immunohistochemistry and elevated prolactin levels (650-6,500 ng/mL).
Findings:
- Medical management with cabergoline effectively normalized prolactin levels.
- Dopamine agonist therapy induced significant tumor shrinkage in these cases.
- Prompt diagnosis and treatment are key to managing these rare pituitary tumors.
Implications:
- Measurement of prolactin levels is recommended for all large skull base tumors in the pituitary region.
- This diagnostic step can prevent misdiagnosis, inappropriate surgery, or radiotherapy.
- Early identification and treatment with dopamine agonists offer a viable therapeutic strategy for giant prolactinomas.